Crown Laboratories Acquires StriVectin from L Catterton

August 26, 2021

Crown Laboratories, a Hildred Capital portfolio company, has entered into a definitive agreement to acquire StriVectin from L Catterton. StriVectin will operate as a wholly owned subsidiary within Crown's new Premium Skincare Division, with its president Cori Aleardi joining Crown's executive team; the deal was expected to close by mid-September 2021.

Buyers
Crown Laboratories
Targets
StriVectin
Sellers
L Catterton
Platforms
Crown Laboratories
Location
New York, United States
Transaction Type
Addon

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.